Matteo Costantino

Via Amadeo 42
Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA Repair.

USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA Repair.

Journal: International journal of biological sciences

Published: December 22, 2025

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors.

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: April 16, 2025

PSMC6 regulation of ovarian cancer cisplatin resistance unravels a new mode for proteasome targeting.

PSMC6 regulation of ovarian cancer cisplatin resistance unravels a new mode for proteasome targeting.

Journal: International journal of biological sciences

Published: October 03, 2024

Deubiquitinases in Ovarian Cancer: Role in Drug Resistance and Tumor Aggressiveness.

Deubiquitinases in Ovarian Cancer: Role in Drug Resistance and Tumor Aggressiveness.

Journal: International journal of biological sciences

Published: July 01, 2024

Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.

Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.

Journal: Current medicinal chemistry

Published: December 29, 2023

The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis.

The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis.

Journal: Frontiers in cell and developmental biology

Published: September 27, 2022

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma.

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma.

Journal: Frontiers in cell and developmental biology

Published: April 23, 2022

P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: Evidence for a role of tau in cancer.

P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: Evidence for a role of tau in cancer.

Journal: Biochemical pharmacology

Published: April 05, 2022

Curcumin and Related Compounds in Cancer Cells: New Avenues for Old Molecules.

Curcumin and Related Compounds in Cancer Cells: New Avenues for Old Molecules.

Journal: Frontiers in pharmacology

Published: March 04, 2022

Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.

Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.

Journal: Biochemical pharmacology

Published: October 21, 2021

The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets.

The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets.

Journal: Current medicinal chemistry

Published: June 01, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026